New study to deepen understanding of a weight loss medication
Health Innovation Manchester and 糖心Vlog官方 has today (14 October 2024) announced a groundbreaking strategic partnership with Eli Lilly and Company (Lilly) to initiate a five-year real-world evidence study (SURMOUNT-REAL UK), subject to relevant approvals.
The announcement has been made as part of a collaboration agreed between Lilly and UK Government today, unveiled at the Government鈥檚 International Investment Summit.
The study will evaluate the real-world effectiveness of tirzepatide in weight loss, diabetes prevention, and prevention of obesity-related complications for adults with obesity.
The evidence generated will seek to increase the global evidence base on the long-term impacts of weight loss medicines and potentially inform the UK's care pathway approach to the treatment of obesity. Significantly, the five-year study will also aim to collect data on healthcare resource utilisation, health-related quality of life and changes in participants鈥� employment status and sick days from work.
Health Innovation Manchester has worked with the University of Manchester and local digital trials company NorthWest EHealth to develop the study approach.
Mayor of Greater Manchester, Andy Burnham, said: 鈥淕reater Manchester is worldrenowned as a hub for innovation in health and life sciences. The results of the trial announced today could have a far-reaching impact on how we treat obesity globally, and our city-region is ready to make a significant contribution through our outstanding health data assets, R&D expertise, and the strong partnerships between industry, universities and public sector organisations.
鈥淭he International Investment Summit will provide an opportunity to showcase our local strengths in health innovation to an audience of global business leaders and investors. This partnership could be the first of many and give Greater Manchester residents access to other innovative treatments.鈥�
This five-year real-world study aims to demonstrate the long-term efficacy and safety profile of tirzepatide in a primary care setting compared to usual care. It will specifically quantify the medicine鈥檚 long-term effects on obesity, diabetes incidence, and obesity-related complications, as well as its impacts on employment and health economic outcomes
Professor Rachel Batterham, Senior Vice President for International Medical Affairs at Lilly, said: 鈥淎t Lilly, we are deeply committed to improving lives by partnering across the health system to address complex health challenges like obesity. We鈥檙e delighted to partner with Health Innovation Manchester on our plans for the SURMOUNT-REAL UK study. This collaboration will add to the evidence base on the real world impact of obesity treatments on the health of people with obesity, and will explore a broad range of outcomes including health-related quality of life and impact on individuals鈥� employment status.鈥�
Martin Rutter, Professor of Cardiometabolic Medicine, University of Manchester, and principal investigator for the Greater Manchester study, said: 鈥淭his five-year real-world study aims to demonstrate the long-term efficacy and safety profile of tirzepatide in a primary care setting compared to usual care. It will specifically quantify the medicine鈥檚 long-term effects on obesity, diabetes incidence, and obesity-related complications, as well as its impacts on employment and health economic outcomes.鈥�
Ben Bridgewater, CEO at Health Innovation Manchester, commented: 鈥淕reater Manchester (GM) is well placed to deliver novel trials and real-world evidence studies to develop a deeper understanding of the impact that industry-led innovation can have on population health. Through this landmark partnership with Lilly we will show how a medicine impacts people鈥檚 long-term health outcomes. This will help us understand its effects people with obesity in GM as well as inform national strategies and pave the way for further research and development in this critical area.鈥�
Mark Britnell, Chair of Health Innovation Manchester, said: 鈥淥wing to our strengths in life sciences, academia and digital, Greater Manchester has all the ingredients to be truly world-leading in health innovation. This is demonstrated through our partnership with Lilly, which will help to propel our sector strengths even further forward for the benefit of local patients.鈥�
Mark Fisher, CEO of the NHS Greater Manchester Integrated Care Board, said: 鈥淎round 600,000 adults in Greater Manchester live with obesity, many of whom also suffer with other obesity-related illnesses which reduces their quality of life and puts additional pressure on the health and care system. Working collaboratively with industry to solve these problems is paramount, and I am delighted to support the study coming to the Greater Manchester integrated care system.鈥�
Jonathan Wogel, Chief Executive Officer, NorthWest EHealth, said: 鈥淲e are excited to be partnering with our colleagues at Health Innovation Manchester to deliver this new study which is aimed at generating data to support patients with obesity. It is not only a milestone for NWEH and Greater Manchester (GM), but a significant moment for the UK clinical trials industry. By combining GM鈥檚 well established health system with our innovative technology, we are demonstrating the future of clinical trials, where technology and health data integrate to make research more efficient, helping develop and deliver better care for patients.鈥�